In accordance with article 5 of the Spanish Law RDL1/2015, the information set out in the following sections is intended for healthcare professionals.
Access to this information and all use which may be made thereof or of these contents is exclusive responsibility of those who use them. Noventure will not be held liable for any illegal or improper use or for the manipulation of the contents and information included in these pages.
Magazine
We are pleased to announce the launch of Rhinosectan® in its first market, Spain.
The product is commercialized under the brand Rinonet/Rhinosectan®, is distributed by Laboratorios SALVAT S.A.and has been available as 15 ml solution for intranasal application in pharmacies across Spain since May.
A new class of non-drug treatments for rhinitis of various origins is gaining momentum. Among them, Xyloglucan stands out as a natural substance with a well-defined mode of action…
Noventure is proud to announce that Medexport has signed an agreement for the distribution of Utipro Plus AF in Kazakhstan